NCT03889275: A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors

NCT03889275
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 101 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT03889275

Comments are closed.

Up ↑